Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528905 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00528905 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 400 participants.
The verdict
NCT00528905, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used in future trials.
Interventions
- DRUG AZD3480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528905
The ClinicalTrials.gov registry entry for NCT00528905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD3480 is the first listed.
NCT00528905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528905 about?
NCT00528905 is a clinical study titled "Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia". The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used i...
What is the current status of trial NCT00528905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2007-08. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00528905?
The interventions under investigation include: AZD3480 (DRUG).
Who is sponsoring clinical trial NCT00528905?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.